Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03031899
Other study ID # 219/2014-15
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 2015
Est. completion date March 2016

Study information

Verified date March 2018
Source The Oxford Dental College, Hospital and Research Center, Bangalore, India
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Abstract

Objective:

To study the diagnostic efficiency of Rose Bengal with Toluidine blue in detecting the biopsy sites and thus establish an accurate diagnosis in oral premalignant lesions.

Materials and method:

In our study 27 patients with 41 lesions were included. Since one patient had not quit the habit in the two weeks following initial examination and another lesion disappeared in the waiting period, 2 patients (3 lesions) were not included in the study. Out of 38 lesions diagnosed based on clinical criteria, 32 were leukoplakia, 5 lichen planus and 1 SCC. After initial examination they were subjected to Rose Bengal and Toluidine blue stain. If stained positive they were subjected to biopsy.


Description:

Introduction Toluidine blue staining is the most common technique used for the early detection of dysplastic changes in patients with premalignant lesions. One meta-analysis of Rosenberg et al. previously published reported sensitivity ranged from 93.5% to 97.8% and the specificity ranged from 73.3% to 92.9%. Zang et al reported that TB not only detects high-grade dysplasia but detects OPLs with minimal or no dysplasia with high-risk clinical and molecular attributes.4 But, studies have shown as high as 30% risk of false-positive staining.

Rose Bengal (RB) has been widely used to diagnose various ocular surface disorders including delineation of the extent of corneal and conjunctival neoplasms. It has been believed to stain desquamated ocular epithelial cells, dead or degenerated cells, or wherever there is poor protection of the surface epithelium by the preocular tear film rather than lack of cell vitality. These characteristic features of RB lead the researchers to apply it in oral premalignant lesions.5 In none of the studies, reliability of RB stains was not compared with existing or previously practiced methods in oral premalignant lesions. Hence this study was undertaken with the aim of comparing the RB and TB stain and for early detection of dysplasia in oral premalignant lesions.

Materials and Methods:

Study group consists of 41 oral premalignant lesions in patients visiting the Department of Oral Medicine and Radiology of The oxford dental college and hospital, Bangalore. Patients with OSMF, patients with bleeding disorders, patient with other systemic diseases were excluded from the study.To perform the present study, ethical clearance was obtained from the Institutional Ethical Board. Study procedure was explained and informed consent was taken from the selected patients with premalignant lesions. The patients with lesions were subjected to detailed case history, intra oral examination and photographs of the lesions were recorded. Patients with habits were counselled to quit the habit and recalled after 2 weeks for staining. Since one patient had not quit the habit in the two weeks from first visit, in another patient the lesion disappeared in two weeks 2 patients (3 lesions) were not included in the study. (Graph1)

Initially patients were asked to rinse their mouth with distilled water for 1 minute. 1% RB solution was applied with a cotton tip for 2 minutes. Again patients were asked to rinse their mouth for 1 minute with distilled water to remove excess RB solution and the area which had taken up the stain was photographed. Following this, patients were asked to rinse their mouth with 1% acetic acid for 1 min to remove the remaining RB stain from the lesion and were prepared for TB staining. 1%Toluidineblue is applied over the lesion and after 30 seconds patients were made to swish with 1% acetic acid and the area stained was recorded photographically.

These two photographs were assessed and if the stained area was similar in both the procedures single biopsy was taken. If the stained areas were different two different biopsies were taken.


Recruitment information / eligibility

Status Completed
Enrollment 27
Est. completion date March 2016
Est. primary completion date March 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients with clinically diagnosed oral premalignant lesions (oral leukoplakia and oral lichen planus).

Exclusion Criteria:

- Patients with OSMF

- bleeding disorders and

- other systemic diseases

Study Design


Intervention

Procedure:
Biopsy
rose bengal stain and toluidine is applied over a premalignant lesion and positively stained lesions are subjected to biopsy.
Diagnostic Test:
Rose Bengal
the lesions stained positive were subjected to biopsy
toluidine blue
the lesions stained positive were subjected to biopsy

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
The Oxford Dental College, Hospital and Research Center, Bangalore, India

Outcome

Type Measure Description Time frame Safety issue
Primary Number and Percentage of Lesions That Were Stained Positive outcome measure1 2 weeks
Primary Sensitivity and Specificity (Percentage of True Positives and True Negatives) sensitivity: Percentage of lesions stained positive with Toluidine blue stain that were also stained positive with Rose Bengal stain specificity: Percentage of lesions stained negative with Toluidine blue stain that were also stained negative with Rose Bengal stain 2 weeks
Secondary Presence of Dysplasia in Biopsied Lesions That Were Stained by Rose Bengal this outcome measure was limited to the biopsied lesions.additionally, the intent of this outcome measure was only to study early detection of dysplasia in oral premalignant lesions using the Rose bengal stain. (no comparison between the two stains were intended ) 2 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05997173 - The Regulatory Role of Immune Response in Oral Lichen Planus
Completed NCT02443311 - Clinical and Immunohistochemical Effect of Topical Pimecrolimus in Treatment of Oral Lichen Planus Phase 4
Completed NCT00484250 - Study of Metronidazole and Doxycycline to Treat Oral Lichen Planus and to Compare Their Efficacy With Each Other Phase 2
Completed NCT03682562 - Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions
Not yet recruiting NCT06428630 - Systemic Absorption of Dexamethasone Oral Rinse in Patients With Oral Lichen Planus Early Phase 1
Completed NCT04193748 - Evaluation of Topical Pomegranate Extracts in Management of Oral Lichen Planus (A Randomized Clinical Trial) Phase 4
Completed NCT04153266 - Oral Epithelial Dysplasia Informational Needs Questionnaire
Recruiting NCT06135805 - Impact of Fluocinonide 0,05% in Oral Lichen Planus N/A
Completed NCT04289233 - Molecular & Cellular Characterisation of Oral Lichen Planus
Completed NCT04293718 - Acquired Chronic Erosive Gingivitis: Clinical Relevance of Papillary Gingival Biopsy
Completed NCT00525421 - A Clinical Study of Curcuminoids in the Treatment of Oral Lichen Planus Phase 2
Not yet recruiting NCT04091698 - Clinical and Biochemical Assessment of the Effect of Topical Use of Coenzyme Q10 Versus Topical Corticosteroid in Management of Symptomatic Oral Lichen Planus: Randomized Controlled Clinical Trial Phase 1
Completed NCT03386643 - Effect of Bifidobacterium Animalis Subsp. Lactis HN019 on Oral Lichen Planus Phase 2
Withdrawn NCT03836885 - Apremilast - Oral Lichen Planus Trial Phase 2
Completed NCT05730855 - Diagnostic Accuracy of lncRNA DQ786243 and miRNA146a in Saliva of Oral Potentially Malignant Lesions
Completed NCT03257228 - The Association Between Diabetes Mellitus, Oral Lichen Planus and Insulin-like Growth Factors 1 and 2 (IGF1 and IGF2) N/A
Recruiting NCT03026478 - Topical Betamethasone and Clobetasol in Orabase in Oral Lichen Planus Phase 2
Completed NCT02834520 - Expression of miRNa-138 and Cyclin D1 in Oral Mucosa of Patients With Oral Lichen Planus N/A
Completed NCT02858297 - Glucosamine as a Novel Adjunctive Therapy in Oral Lichen Planus Phase 4
Completed NCT02106468 - The Efficacy of Omega-3 in Treatment of Atrophic/Erosive Lichen Planus Phase 2